1. Tardif JC, Pandian NG. Intravascular ultrasound imaging in peripheral damarial and coronary damary disease. Curr Opin
Cardiol 1994; 9: 627-33.
2. Haasdai D, Behar S, Wallentin L, et al. A prospective survey of the characteristics, treatment and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur Heart J 2002; 23: 1190-201.
3. Hausmann D, Erbel R, Alibelli-Chemarin MJ, et al. The safety of intracoronary ultrasound: amulticnter survey of 2207 examinations. Circulation 1995; 91: 623-30.
4. Pinto FJ, St Goar F, Gao SZ, et al. Immediate and one year safety of intracoronary ultrasonic imaging: evaluation with serial quantitative angiography. Circulation 1993; 88: 1709-14.
5. Ramasubbu K, Schoenhagen P, Balghith MA, et al. Repeated intravascular ultrasound imaging in cardiac transplant recipients does not accelerate transplant coronary artery disease. J Am Coll
Cardiol 2003; 41: 1739-43.6. Mintz GS, Pichard AD, Kovach JA, Kent KM, Satler LF, Javier
SP et al. Impact of preintervention intravascular ultrasound imaging on transcatheter treatment strategies in coronary artery
disease. Am J Cardiol 1994; 73: 423-30.
7. Nakamura S, Colombo A, Gaglione A, Almagor Y, Goldberg SL, Maiello L et al. Intracoronary ultrasound observations during
stent implantation. Circulation 1994; 89: 2026-34.
8. Tobis JM, Mahon DJ, Goldberg SL, et al. Lessons from intravascular ultrasonography: observations during interventional angioplasty procedures. J Clin Ultrasound 1993; 21: 598-607.
9. Kasaoka S, Tobis JM, Akiyama T, et al. Angiographic and intravascular ultrasound predictors of in-stent restenosis. J Am Coll Cardiol 1998; 32: 1630-5.
10. Moussa I, Di Mario C, Reimers B, et al. Subacute stent trombosis in the era of intravascular ultrasound-guided coronary stenting withouth anticoagulation : frequency, predictors and clinical
outcome. J Am Coll Cardiol 1997; 29: 6-12.12. Tuzcu EM, Kapadia SR, Sachar R, et al. Intravascular ultrasound evedince of angiographically silent progression in coronary atherosclerosis predicts lon-term morbidity and mortality after cardiac transplantation.
13. Glagov S, Weisenberg E, Zarins CK, et al. Compensatory enlargement of human atherosclerotic coronary damaries. N Eng
J Med 1987; 316: 1371-5.
14. Ito K, Yamagishi M, Yaasumura Y, et al. Impact of coronary damary remodeling on misinterpreration of angiographic disease eccentricity: evidence from intravascular ultrasound. Int J Cardiol
1999; 70: 275-82.
15. Sipahi I, Tuzcu EM, Schoenhagen P, Nicholls SJ, Kapadia S, Nissen SE: Paradoxical Increase in Lumen Size During Progres¬sion of Coronary Atherosclerosis: Observations from The
REVERSAL Trial. Atherosclerosis 2006 (in press)
16. Sipahi I, Tuzcu EM, Schoenhagen P, Nicholls SJ, Crowe T, Kapadia S, Nissen SE: Discordance between Static and Serial Assessments of Arterial Remodeling: An Intravascular Ultrasound Analysis from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Trial. Am Heart J
2006 (in press)
17. Schoenhagen P, Ziada KM, Kapadia SR, et al. Extent and direction of damarial remodeling in stable and unstable coronary
syndromes. Circulation 2000; 101: 598-603.
18. Schoenhagen P, Vince DG, Ziada KM, et al. Relation of matrix-metalloproteinase 3 found in coronary lesion samples retrieved by directional coronary atherectomy to intravascular ultrasound observations on coronary remodeling. Am J Cardiol 2002; 89:
1354-9.
Tuzcu ve Ark.
19. Mintz GS, Painter JA, Pichard AD, et al. Atherosclerosis in angiographically "normal"
coronar
y damary reference segments: an intravascular ultrasound study with clinical correlations. J Am Coll Cardiol 1995; 25: 1479-85.
20. Nair A, Kuban BD, Tuzcu EM, et al. Coronary plaque classification with intravascular ultrasound radiofrequency data
analysis. Circulation 2002; 106: 2200-6.
21. Schaar JA, De Korte CL, Mastik F, et al. Characterizing vulnerable plaque features with intravascular elastography. Circulation 2003;108:2636-41
22. Jukema JW, Bruschke AV, van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary damary disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression
Growth Evaluation Statin Study (REGRESS). Circulation 1995;
91: 2528-40.
23. Nissen SE, Tuzcu EM, Schoenhagen P, et al. REVERSAL
Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a
randomized controlled trial. JAMA 2004; 291: 1071-80.
24. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Eng J Med 2004; 350: 1495-504.
25. Nissen SE, Tuzcu EM, Libby P, et al. CAMELOT Investigaters.
Effects of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the
CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217-25.
Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomize controlled trial. JAMA 2003;
290: 2292-300.
26. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculapathy in cardiac
transplant recipients. N Engl J Med. 2003; 349: 847-58.
Thank you for copying data from http://www.arastirmax.com